Breaking News

BMS Acquires iPierian

April 29, 2014

Gains lead preclinical asset for neurodegenerative diseases

Bristol-Myers Squibb has acquired iPierian, a privately held biopharma company, for $175 million, with the potential for additional development and regulatory milestones totaling $550 million, as well as future royalties on sales.
 
iPierian focuses on developing treatments for Tauopathies, a class of neurodegenerative diseases associated with the Tau protein in the human brain. With the acquisition, BMS gains full rights to iPierian’s lead asset IPN007, a monoclonal antibody with a promising new approach to treat progressive supranuclear palsy (PSP) and other Tauopathies, scheduled to enter Phase I trials by early 2015.
 
“As part of our evolution to a diversified specialty BioPharma company, we have identified genetically defined diseases as an area where the company has an opportunity to significantly advance the standard of care for patients with limited treatment options,” said Francis Cuss, executive vice president and chief scientific officer, Bristol-Myers Squibb. “The acquisition of iPierian supports our growing efforts in this area and builds on Bristol-Myers Squibb’s internal expertise and alliances focused on the Tau pathway and neurodegenerative diseases.”
 
“iPierian’s discovery of a novel mechanism of secreted Tau biology was the basis of the IPN007 program,” said Dr. Nancy Stagliano, chief executive officer of iPierian. “The acquisition reinforces the importance of this finding and we are gratified that IPN007 is strongly positioned now to potentially offer a new therapeutic option to progressive supranuclear palsy patients.”

blog comments powered by Disqus
  • Cold Chain Packaging Trends

    Cold Chain Packaging Trends

    Kristin Brooks, Contract Pharma||February 4, 2016
    Susan Li of UPS discusses supply chain trends, challenges, and packaging innovations

  • Packaging Equipment Trends Preview

    Packaging Equipment Trends Preview

    Kristin Brooks, Contract Pharma||January 26, 2016
    Christian Treitel of Bosch Packaging Technology discusses trends and capabilities

  • Filings Update

    Filings Update

    December 1, 2015
    Roche, Pfizer, Janssen, BMS and more

  • Elemental Impurity Testing

    Elemental Impurity Testing

    Dr. Andrew Fussell, PANalytical ||January 28, 2016
    Advances in elemental impurity testing aid compliance with new USP requirements

  • Fit-For-Purpose Assay Development in Bioanalysis

    Fit-For-Purpose Assay Development in Bioanalysis

    Franklin Spriggs, Ligand Binding Assay Group Leader; Ashley Brant, Program Manager, AIT Bioscience||January 28, 2016
    The success of bioanalytical studies relies on the selection of the most suitable analytical method but the timeline of method development and types of analyses involved vary greatly.

  • Optimizing Collaboration Effectiveness in Alliance Partnerships

    Optimizing Collaboration Effectiveness in Alliance Partnerships

    Mary Jo Lamberti, Phil Birch, Ranjana Chakravarthy, Ken Getz, Tufts CSDD||January 28, 2016